VKH
EVOK

Virtu KCG Holdings’s Evoke Pharma EVOK Stock Holding History

Virtu KCG Holdings’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-109
Closed -$49K – 3032
2017
Q1 		$49K Sell
109
-12
-10% -$4.92K ﹤0.01% 2849
2016
Q4 		$35K Buy
+121
New +$31.3K ﹤0.01% 3161

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PM
Precept Management Dallas, Texas $126M AUM 36.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Virtu KCG Holdings's EVOK Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Evoke Pharma (EVOK) in Q2 2017, closing a stake of 109 shares — an estimated $49K sold.

Virtu KCG Holdings first reported a position in EVOK in Q4 2016 and held it in 2 quarters. The position peaked at $49K in Q1 2017. 21 funds tracked by Wall St. Rank hold EVOK as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Evoke Pharma position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 109 Evoke Pharma shares in Q2 2017, an estimated $49K.
  • Virtu KCG Holdings first reported a position in Evoke Pharma in Q4 2016 and held it in 2 quarters.
  • Virtu KCG Holdings's Evoke Pharma position peaked at $49K in Q1 2017.
  • 21 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.